Skip to content

Study · Observational study · n = 5 · 2013

5 results

Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy.

Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E

Bone13 Oct 2012Cited by 99 (Europe PMC)

PMID23072919 (opens in a new tab)DOI10.1016/j.bone.2012.10.006 (opens in a new tab)PepBankPUB-23072919
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with bisphosphonate-associated atypical femoral fractures, teriparatide treatment was linked to increased bone remodelling markers.

    In plain wordsIn patients with atypical femoral fractures, teriparatide treatment was linked to increased bone remodelling markers.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone remodelling markers
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Marker increase
    2 to 3 fold
    teriparatide-treated patients

    Source sentences

    Summary
    Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing.
    1 context sentence
    Summary · context
    A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture.
  2. 02HumanObservational studyEfficacy outcome

    In patients with bisphosphonate-associated atypical femoral fractures, teriparatide treatment was linked to fracture healing.

    In plain wordsIn patients with atypical femoral fractures, teriparatide treatment was linked to fracture healing.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFracture healing
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing.
    1 context sentence
    Summary · context
    A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture.
  3. 03HumanObservational studyEfficacy outcome

    In teriparatide-treated patients with atypical femoral fractures, the proportion of less densely mineralised radius bone increased from baseline.

    In plain wordsIn patients with atypical fractures, teriparatide treatment was linked to more less densely mineralised radius bone than at baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLess mineralised bone at radius
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Proportion increase
    29.5%
    distal radius

    Source sentences

    Summary
    At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03).
    2 context sentences
    Summary · context
    A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture.
    Summary · context
    Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing.
  4. 04HumanObservational studyEfficacy outcome

    In teriparatide-treated patients with atypical femoral fractures, the proportion of older, more densely mineralised radius bone decreased from baseline.

    In plain wordsIn patients with atypical fractures, teriparatide treatment was linked to less older, densely mineralised radius bone than at baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMore mineralised bone at radius
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Proportion decrease
    16.2%
    distal radius

    Source sentences

    Summary
    At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03).
    2 context sentences
    Summary · context
    A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture.
    Summary · context
    Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing.
  5. 05HumanObservational studyEfficacy outcome

    In teriparatide-treated patients with atypical femoral fractures, similar mineralisation density observations were reported at the distal tibia as at the radius.

    In plain wordsIn patients with atypical fractures given teriparatide, tibial bone mineralisation showed observations similar to those at the radius.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedBone mineralisation density distribution at tibia
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Similar observations were made at the distal tibia.
    3 context sentences
    Summary · context
    At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03).
    Summary · context
    A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture.
    Summary · context
    Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.